Candriam Luxembourg S.C.A. lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 28.3% during the second quarter, Holdings Channel reports. The firm owned 170,000 shares of the biopharmaceutical company’s stock after selling 67,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Vanda Pharmaceuticals were worth $2,771,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Virginia Retirement Systems ET AL acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth $193,000. Capital Fund Management S.A. acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth $195,000. AQR Capital Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $223,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter worth $196,000. Finally, Algert Global LLC boosted its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 1,927 shares during the period. 91.42% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 15.40 on Thursday. The firm has a 50-day moving average of $16.19 and a 200-day moving average of $14.68. The stock’s market capitalization is $688.66 million. Vanda Pharmaceuticals Inc. has a 52-week low of $11.58 and a 52-week high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. The company had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period last year, the business posted $0.01 EPS. On average, equities analysts expect that Vanda Pharmaceuticals Inc. will post ($0.61) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Candriam Luxembourg S.C.A. Reduces Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-reduces-stake-in-vanda-pharmaceuticals-inc-nasdaqvnda/1468811.html.

A number of research firms have weighed in on VNDA. Oppenheimer Holdings, Inc. set a $21.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research report on Tuesday. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, May 25th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $21.33.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.